Dr. Wang Discusses Acalabrutinib in MCL

Michael Wang, MD
Published: Thursday, Dec 21, 2017



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.

Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.

Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x